Description du projet
Ouvrir la voie à l’apprentissage automatique en chimie
Afin de faire progresser la chimie médicinale, la prochaine génération de scientifiques devra disposer de connaissances poussées en chimie, ainsi qu’en matière de technologies avancées telles que l’intelligence artificielle (IA) et l’apprentissage automatique. Le projet AIDD, financé par l’UE, tentera d’innover dans le domaine de la recherche médicamenteuse, en formant une nouvelle génération de scientifiques disposant de compétences en matière d’apprentissage automatique. Il s’agit d’un atout essentiel pour le développement de l’industrie chimique, notamment représentée par des entreprises pharmaceutiques, des sociétés de biotechnologies agricoles, ainsi que d’autres entreprises dans le domaine de la chimie. Les chercheurs boursiers ainsi employés seront supervisés par des universitaires présentant une excellente expertise complémentaire, ayant également contribué au développement de certains algorithmes d’IA fondamentaux utilisés des milliards de fois chaque jour dans le monde, mais également par des entreprises pharmaceutiques de premier plan en UE, responsables du développement de nouveaux médicaments et de la santé publique.
Objectif
"The dramatic increase in using of Artificial Intelligence (AI) and machine learning methods in different fields of science becomes an essential asset in the development of the chemical industry, including pharmaceutical, agro biotech, and other chemical companies. However, the application of AI in these fields is not straightforward and requires excellent knowledge of chemistry. Thus, there is a strong need to train and prepare a new generation of scientists who have skills both in machine learning and in chemistry and can advance medicinal chemistry, which is the prime goal of the AIDD proposal. Research WPs include sixteen topics selected to cover the key innovative directions in machine learning in chemistry. Fellows employed will be supervised by academics who have excellent complementary expertise and contributed some of the fundamental AI algorithms which are used billions of times per day in the world, and leading EU Pharma companies who are in charge of new medicine and public health. All developed methods can be used individually but will also contribute to an integrated ""One Chemistry"" model that can predict outcomes ranging from different properties to molecule generation and synthesis. Training on various modalities allows the model to understand how to intertwine chemistry and biology to develop a new drug making its design robust and explainable. All partners agreed to make their software open source. It will boost the field and will provide the broadest possible dissemination of the results both to the academy and industry, including SMEs. The network will offer comprehensive, structured training through a well-elaborated Curriculum, online courses, and six Schools. The IP policy and commercial exploitation of the project results have the highest priority supported by intellectual property asset management organizations. Comprehensive public engagement activities will complement the dissemination of results to the scientific community."
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencescomputer and information sciencessoftware
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicinemedicinal chemistry
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Mots‑clés
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
85764 Neuherberg
Allemagne